Clinical cure can be achieved in some patients with early stage prostate cancer, but it is difficult to achieve a complete cure in the traditional sense of the word; one study claims a 5-year overall survival rate of 78.9%. Prostate cancer is one of the common malignant tumors in older men, and according to 2018 statistics, it is the most common malignant tumor in Western men and ranks second in tumor-related deaths. The incidence of prostate cancer in China is lower than that in western countries, but it has been on the rise in the last decade or so, and has become one of the most important diseases threatening men’s health in China. The prognosis of malignant tumors is usually described by “3-year/5-year survival rate”. The prognosis of prostate cancer is closely related to the age at first diagnosis, PSA level at first diagnosis, Gleason total score and distant metastasis of the cancer, etc. According to some studies, the overall survival rates of prostate cancer patients at 1, 3 and 5 years are 96.0%, 87.3% and 78.9%, respectively. For patients with early stage prostate cancer, if surgical contraindications are excluded, most of them can be clinically cured through radical prostate cancer surgical resection. For patients with contraindications to surgery, radical radiotherapy, or combined endocrine therapy/chemotherapy can also be used to achieve a good prognosis. For the treatment of prostate cancer, it is recommended that patients go to regular hospitals in time, so as not to delay the treatment of the disease.